[
    {
        "title": "Coverage of the Renters\u2019 Rights Act becoming law",
        "authors": [
            "mhclgpress"
        ],
        "posted_on": "2025-10-28T16:56:40",
        "categories": [
            "Uncategorized"
        ],
        "content": [
            {
                "content": "There has been widespread national, trade and broadcast coverage on the department\u2019s\u00a0announcement\u00a0on the Renters\u2019 Rights Bill receiving Royal Assent.",
                "tag": "p"
            },
            {
                "content": "England\u2019s 11 million private renters will have significant increase to their rights in a generation as the government\u2019s Renters\u2019 Rights Bill received Royal Assent.",
                "tag": "p"
            },
            {
                "content": "National coverage can be seen on\u00a0BBC News online highlighting key measures of protection for private renters including abolishing no-fault evictions, limiting rent increases to once a year at market rate and limiting upfront deposits to one month rent. The Telegraph,",
                "tag": "p"
            },
            {
                "content": "Independent and ITV News online write explainer pieces on how rental reforms will affect tenants and landlords.",
                "tag": "p"
            },
            {
                "content": "Across broadcast, BBC News and ITV News both ran packages across their evening news bulletins yesterday noting the greater protections for renters. BBC Radio 4\u2019s Today Programme also featured the announcement noting that the Housing Minister has had to go back and forth on amendments with the Lords on the Act.",
                "tag": "p"
            },
            {
                "content": "City AM and the Big Issue focus on comments from the Prime Minister who said the government was \u201cputting an end\u201d to \u201crogue landlords or insecure contracts\u201d. The Metro also carries exclusive words from the Housing Secretary explaining that the Bill the bill would \u2018transform the experience of private renting\u2019.",
                "tag": "p"
            },
            {
                "content": "The Secretary of State also took part in lunchtime interviews today with ITN, Jeremy Vine on Radio 2, World at One on Radio 4 and Radio 5 Live. A piece on the Andrew Marr show on LBC is also due to run this evening.",
                "tag": "p"
            },
            {
                "content": "Prime Minister Keir Starmer said:",
                "tag": "p"
            },
            {
                "content": "\u201cEvery family deserves the dignity of a safe and secure home.\u00a0\u00a0",
                "tag": "p"
            },
            {
                "content": "\u201cFor too long, millions of renters have lived at the mercy of rogue landlords or insecure contracts, with their futures hanging in the balance. We\u2019re putting an end to that.\u00a0\u00a0",
                "tag": "p"
            },
            {
                "content": "\u201cA secure home isn\u2019t just bricks and mortar \u2013 it\u2019s the foundation for opportunity, safety, and a better life. No child should grow up without one.\u201d\u00a0",
                "tag": "p"
            },
            {
                "content": "Secretary of State Steve Reed said:",
                "tag": "p"
            },
            {
                "content": "\u201cOur historic Act marks the biggest leap forward in renters\u2019 rights in a generation. We are finally ending the injustice overseen by previous governments that has left millions living in fear of losing their homes.\u00a0\u00a0\u00a0",
                "tag": "p"
            },
            {
                "content": "\u201cFor decades, the scales have been tipped against tenants. Now, we\u2019re levelling the playing field between renters and landlords.\u00a0\u00a0",
                "tag": "p"
            },
            {
                "content": "\u201cWe are tearing down the walls of injustice in the private rented sector and building a future where tenants are protected, respected and empowered.\u00a0\u00a0",
                "tag": "p"
            },
            {
                "content": "\u201cThis is an historic moment for renters across the country and we\u2019re proud to deliver it.\u201d\u00a0\u00a0",
                "tag": "p"
            }
        ],
        "link": "https://mhclgmedia.blog.gov.uk/2025/10/28/coverage-of-the-renters-rights-act-becoming-law/",
        "blog": "MHCLG in the Media",
        "blog_link": "https://mhclgmedia.blog.gov.uk",
        "description": "There has been widespread national, trade and broadcast coverage on the department\u2019s\u00a0announcement\u00a0on the Renters\u2019 Rights Bill receiving Royal Assent. England\u2019s 11 million private renters will have significant increase to their rights in a generation as the government\u2019s Renters\u2019 Rights Bill \u2026"
    },
    {
        "title": "Clinical trials regulations: six-month countdown begins",
        "authors": [
            "James Pound"
        ],
        "posted_on": "2025-10-28T15:55:11",
        "categories": [
            "Clinical Trials"
        ],
        "content": [
            {
                "content": "In six months\u2019 time, on 28 April 2026, the most significant update to UK clinical trials regulations in two decades will come into force.",
                "tag": "p"
            },
            {
                "content": "This will be a pivotal moment for the evolving clinical trial landscape and marks a new way forward for how trials involving medicinal products are set up and delivered across the UK.",
                "tag": "p"
            },
            {
                "content": "Together, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA) have developed amended regulations that have been shaped by - and will benefit - patients, researchers, health professionals, and industry.",
                "tag": "p"
            },
            {
                "content": "The updated regulations are designed to protect trial participants, strengthen patient safety, and accelerate approvals by reducing unnecessary burdens on researchers, to support high-quality, trusted research taking place in the UK.",
                "tag": "p"
            },
            {
                "content": "The implementation of the latest international Good Clinical Practice (GCP) guidelines (ICH-GCP E6(R3)) will come into force in the UK, along with the updated regulations. All trials will need to adhere to the principles of GCP, and trials for marketing authorisation will need to comply with the full guidelines.",
                "tag": "p"
            },
            {
                "content": "By streamlining our approvals processes, reducing duplication and supporting a proportionate and flexible approach to regulation, it will be quicker and easier to set up and run clinical trials, while maintaining the highest standards of safety. This will speed up vital research that could lead to new and better treatments for patients.",
                "tag": "p"
            },
            {
                "content": "Greater transparency of clinical trial results will help boost participation, inclusion and diversity. Patients from all backgrounds will feel that their contributions are having a real effect on developing new treatments, placing them at the centre of medical research.",
                "tag": "p"
            },
            {
                "content": "Our joint commitment",
                "tag": "h2"
            },
            {
                "content": "In October 2024, before the regulations had been signed into law, we ran our first joint webinar on the clinical trials regulations where we talked about what the amended regulations would mean for clinical trials in the UK.",
                "tag": "p"
            },
            {
                "content": "We spoke about our commitment to delivering the regulations and what we would do to support their successful implementation. As we reach the six-month countdown to the regulations coming into effect, we\u2019d like to take this opportunity to reaffirm our joint commitment.",
                "tag": "p"
            },
            {
                "content": "MHRA and HRA, together with the devolved governments, have worked together with a wide range of people to develop guidance to support implementation of the regulations. We remain committed to supporting the clinical trial community to be ready for 28 April 2026.",
                "tag": "p"
            },
            {
                "content": "Time to prepare",
                "tag": "h2"
            },
            {
                "content": "The updates to the regulations will result in new ways of working for researchers, sponsors and trial teams, and it will take time to embed new practices.",
                "tag": "p"
            },
            {
                "content": "At the beginning of October 2025, both the MHRA and HRA published guidance which sets out the updates to the regulations and provides practical information for how they should be implemented. MHRA\u2019s guidance is currently still in draft, although minimal adjustments only will be made prior to go live. You can find the latest versions in the MHRA\u2019s Clinical Trials hub. \u00a0",
                "tag": "p"
            },
            {
                "content": "MHRA guidance focuses on issues relevant to MHRA applications and the reporting of key events such as safety information to the MHRA. HRA guidance covers issues related to the REC review of applications, as well as the new transparency requirements. We\u2019ve worked together closely on the guidance to ensure they're aligned, and\u00a0 include links to the other set of guidance.",
                "tag": "p"
            },
            {
                "content": "Based on feedback from stakeholders, our guidance is designed to help those involved in setting up and running clinical trials to navigate the changes and update their polices, processes, procedures and systems ahead of time.",
                "tag": "p"
            },
            {
                "content": "To support a smooth transition, we\u2019re encouraging the clinical trial community to read our guidance and start planning for the changes now. What do you need to review? What can you update now? What do you need to be put in place to ensure you are ready for the 28 April 2026 implementation date?",
                "tag": "p"
            },
            {
                "content": "It\u2019s essential to start having these conversations now, to identify the changes that need to be made as soon as possible, and to create a plan for how they will be implemented.",
                "tag": "p"
            },
            {
                "content": "Looking ahead",
                "tag": "h2"
            },
            {
                "content": "We\u2019re committed to making sure that everyone has the support and information they need, and we\u2019ll be setting up more events and engagement opportunities over the next six months to help researchers and sponsors prepare.",
                "tag": "p"
            },
            {
                "content": "In December 2025, the MHRA will publish a list of changes to definitions. \u00a0",
                "tag": "p"
            },
            {
                "content": "Draft guidance for Good Clinical Practice (GCP) will be published on the MHRA clinical trials hub in January 2026. \u00a0",
                "tag": "p"
            },
            {
                "content": "In March the MHRA will also provide updates to the process for the Modification of an Important Detail (MOID).\u00a0",
                "tag": "p"
            },
            {
                "content": "For the HRA, work continues on developing a set of principles to help sponsors use simplified arrangements for seeking and documenting consent in low intervention clinical trials. The principles will support clinical trials on existing medicines, as legislated in the updated regulations, while ensuring public trust is maintained.",
                "tag": "p"
            },
            {
                "content": "While there are no legislative changes for public involvement and inclusion and diversity as part of the regulatory reforms, new support and guidance will be available for the research community as recommended by the government.",
                "tag": "p"
            },
            {
                "content": "The HRA continues to work with key stakeholders to produce specific guidance for Phase 1 healthy volunteer trials, which will be published alongside existing guidance on involving the public in designing, delivering, and reporting clinical trials.",
                "tag": "p"
            },
            {
                "content": "Joint work between the HRA and MHRA is also ongoing to develop a set of\u00a0questions and supporting guidance\u00a0for researchers to consider when they design clinical trials and clinical investigations. This will help ensure clinical research is designed to include people who could be impacted from its findings, and that people underserved by research are not overlooked.\u00a0",
                "tag": "p"
            },
            {
                "content": "As we look to the future, we also want to take a moment to recognise and thank everyone who has worked with us or provided feedback along the way. We\u2019ll continue to work closely together and talk with and listen to the research community to ensure an effective and successful implementation of the regulations.",
                "tag": "p"
            },
            {
                "content": "Clinical trials regulations guidance",
                "tag": "h2"
            },
            {
                "content": "Read the HRA guidance.",
                "tag": "p"
            },
            {
                "content": "Read the MHRA guidance.",
                "tag": "p"
            }
        ],
        "link": "https://mhrainspectorate.blog.gov.uk/2025/10/28/clinical-trials-regulations-six-month-countdown-begins/",
        "blog": "MHRA Inspectorate",
        "blog_link": "https://mhrainspectorate.blog.gov.uk",
        "description": "In six months\u2019 time, on 28 April 2026, the most significant update to UK clinical trials regulations in two decades will come into force. This will be a pivotal moment for the evolving clinical trial landscape and marks a new \u2026"
    },
    {
        "title": "Clinical trials regulations: six-month countdown begins",
        "authors": [
            "James Pound"
        ],
        "posted_on": "2025-10-28T15:12:41",
        "categories": [
            "Clinical Trials"
        ],
        "content": [
            {
                "content": "In six months\u2019 time, on 28 April 2026, the most significant update to UK clinical trials regulations in two decades will come into force.",
                "tag": "p"
            },
            {
                "content": "This will be a pivotal moment for the evolving clinical trial landscape and marks a new way forward for how trials involving medicinal products are set up and delivered across the UK.",
                "tag": "p"
            },
            {
                "content": "Together, the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA) have developed amended regulations that have been shaped by - and will benefit - patients, researchers, health professionals, and industry.",
                "tag": "p"
            },
            {
                "content": "The updated regulations are designed to protect trial participants, strengthen patient safety, and accelerate approvals by reducing unnecessary burdens on researchers, to support high-quality, trusted research taking place in the UK.",
                "tag": "p"
            },
            {
                "content": "The implementation of the latest international Good Clinical Practice (GCP) guidelines (ICH-GCP E6(R3)) will come into force in the UK, along with the updated regulations. All trials will need to adhere to the principles of GCP, and trials for marketing authorisation will need to comply with the full guidelines.",
                "tag": "p"
            },
            {
                "content": "By streamlining our approvals processes, reducing duplication and supporting a proportionate and flexible approach to regulation, it will be quicker and easier to set up and run clinical trials, while maintaining the highest standards of safety. This will speed up vital research that could lead to new and better treatments for patients.",
                "tag": "p"
            },
            {
                "content": "Greater transparency of clinical trial results will help boost participation, inclusion and diversity. Patients from all backgrounds will feel that their contributions are having a real effect on developing new treatments, placing them at the centre of medical research.",
                "tag": "p"
            },
            {
                "content": "Our joint commitment",
                "tag": "h2"
            },
            {
                "content": "In October 2024, before the regulations had been signed into law, we ran our first joint webinar on the clinical trials regulations where we talked about what the amended regulations would mean for clinical trials in the UK.",
                "tag": "p"
            },
            {
                "content": "We spoke about our commitment to delivering the regulations and what we would do to support their successful implementation. As we reach the six-month countdown to the regulations coming into effect, we\u2019d like to take this opportunity to reaffirm our joint commitment.",
                "tag": "p"
            },
            {
                "content": "MHRA and HRA, together with the devolved governments, have worked together with a wide range of people to develop guidance to support implementation of the regulations. We remain committed to supporting the clinical trial community to be ready for 28 April 2026.",
                "tag": "p"
            },
            {
                "content": "Time to prepare",
                "tag": "h2"
            },
            {
                "content": "The updates to the regulations will result in new ways of working for researchers, sponsors and trial teams, and it will take time to embed new practices.",
                "tag": "p"
            },
            {
                "content": "At the beginning of October 2025, both the MHRA and HRA published guidance which sets out the updates to the regulations and provides practical information for how they should be implemented. MHRA\u2019s guidance is currently still in draft, although minimal adjustments only will be made prior to go live. You can find the latest versions in the MHRA\u2019s Clinical Trials hub. \u00a0",
                "tag": "p"
            },
            {
                "content": "MHRA guidance focuses on issues relevant to MHRA applications and the reporting of key events such as safety information to the MHRA. HRA guidance covers issues related to the REC review of applications, as well as the new transparency requirements. We\u2019ve worked together closely on the guidance to ensure they're aligned, and\u00a0 include links to the other set of guidance.",
                "tag": "p"
            },
            {
                "content": "Based on feedback from stakeholders, our guidance is designed to help those involved in setting up and running clinical trials to navigate the changes and update their polices, processes, procedures and systems ahead of time.",
                "tag": "p"
            },
            {
                "content": "To support a smooth transition, we\u2019re encouraging the clinical trial community to read our guidance and start planning for the changes now. What do you need to review? What can you update now? What do you need to be put in place to ensure you are ready for the 28 April 2026 implementation date?",
                "tag": "p"
            },
            {
                "content": "It\u2019s essential to start having these conversations now, to identify the changes that need to be made as soon as possible, and to create a plan for how they will be implemented.",
                "tag": "p"
            },
            {
                "content": "Looking ahead",
                "tag": "h2"
            },
            {
                "content": "We\u2019re committed to making sure that everyone has the support and information they need, and we\u2019ll be setting up more events and engagement opportunities over the next six months to help researchers and sponsors prepare.",
                "tag": "p"
            },
            {
                "content": "In December 2025, the MHRA will publish a list of changes to definitions. \u00a0",
                "tag": "p"
            },
            {
                "content": "Draft guidance for Good Clinical Practice (GCP) will be published on the MHRA clinical trials hub in January 2026. \u00a0",
                "tag": "p"
            },
            {
                "content": "In March the MHRA will also provide updates to the process for the Modification of an Important Detail (MOID).\u00a0",
                "tag": "p"
            },
            {
                "content": "For the HRA, work continues on developing a set of principles to help sponsors use simplified arrangements for seeking and documenting consent in low intervention clinical trials. The principles will support clinical trials on existing medicines, as legislated in the updated regulations, while ensuring public trust is maintained.",
                "tag": "p"
            },
            {
                "content": "While there are no legislative changes for public involvement and inclusion and diversity as part of the regulatory reforms, new support and guidance will be available for the research community as recommended by the government.",
                "tag": "p"
            },
            {
                "content": "The HRA continues to work with key stakeholders to produce specific guidance for Phase 1 healthy volunteer trials, which will be published alongside existing guidance on involving the public in designing, delivering, and reporting clinical trials.",
                "tag": "p"
            },
            {
                "content": "Joint work between the HRA and MHRA is also ongoing to develop a set of\u00a0questions and supporting guidance\u00a0for researchers to consider when they design clinical trials and clinical investigations. This will help ensure clinical research is designed to include people who could be impacted from its findings, and that people underserved by research are not overlooked.\u00a0",
                "tag": "p"
            },
            {
                "content": "As we look to the future, we also want to take a moment to recognise and thank everyone who has worked with us or provided feedback along the way. We\u2019ll continue to work closely together and talk with and listen to the research community to ensure an effective and successful implementation of the regulations.",
                "tag": "p"
            },
            {
                "content": "Clinical trials regulations guidance",
                "tag": "h2"
            },
            {
                "content": "Read the HRA guidance.",
                "tag": "p"
            },
            {
                "content": "Read the MHRA guidance.",
                "tag": "p"
            }
        ],
        "link": "https://medregs.blog.gov.uk/2025/10/28/clinical-trials-regulations-six-month-countdown-begins/",
        "blog": "MedRegs",
        "blog_link": "https://medregs.blog.gov.uk",
        "description": "In six months\u2019 time, on 28 April 2026, the most significant update to UK clinical trials regulations in two decades will come into force. This will be a pivotal moment for the evolving clinical trial landscape and marks a new \u2026"
    },
    {
        "title": "What\u2019s\u202fchanging\u202f\u2013\u202fSupplementary Protection Certificates\u00a0",
        "authors": [
            "Simeon Bowen"
        ],
        "posted_on": "2025-10-28T14:52:40",
        "categories": [
            "Digital",
            "Innovation",
            "IPO",
            "Patents",
            "Transformation"
        ],
        "content": [
            {
                "content": "Spring 2026 marks the launch of our One IPO Patent Service \u2013 a digital platform that will change how patents are applied for and managed.\u00a0",
                "tag": "p"
            },
            {
                "content": "Our weekly guidance continues with posts covering different elements of the new service. We're working through the key changes to ensure you're fully prepared when the service goes live.\u00a0",
                "tag": "p"
            },
            {
                "content": "This week we're looking at Supplementary Protection Certificates (SPCs) and how they'll work in the new digital environment.\u00a0",
                "tag": "p"
            },
            {
                "content": "What is an SPC?\u00a0",
                "tag": "h3"
            },
            {
                "content": "SPCs are IP rights that last for longer than a standard patent. They are used for pharmaceutical or plant protection products, which typically take a long time to bring to market because they require extensive clinical trials and testing before they can be sold. The extended life of SPCs ensures that rights holders for these products aren\u2019t disadvantaged.\u00a0",
                "tag": "p"
            },
            {
                "content": "Can I apply for SPCs via the new One IPO Service?\u00a0",
                "tag": "h3"
            },
            {
                "content": "You will be able to apply for SPCs via the One IPO Service. There are several benefits to this:\u00a0",
                "tag": "p"
            },
            {
                "content": "However, at launch the SPC functionality will be more limited than for patents. That is because we get a small number of SPC applications per year \u2013 typically less than 100.\u00a0",
                "tag": "p"
            },
            {
                "content": "How will it work?\u00a0",
                "tag": "h3"
            },
            {
                "content": "When you select the option to submit an SPC application, you will be prompted to download and complete a PDF form. Once you have completed the form you will upload it via your account.\u00a0",
                "tag": "p"
            },
            {
                "content": "After approximately five working days you will be able to see your application in the new service. SPCs are listed separately from other patents in your account on their own dedicated page.\u00a0",
                "tag": "p"
            },
            {
                "content": "The process is similar for other actions you may wish to complete on your SPCs, including paying annual SPC fees and applications to extend SPCs. You will find a link to the relevant PDF form and upload it via the new service.\u00a0",
                "tag": "p"
            },
            {
                "content": "The forms for these actions are unchanged from what you\u2019re used to in the existing service.\u00a0",
                "tag": "p"
            },
            {
                "content": "Responding to exam reports for SPCs\u00a0",
                "tag": "h3"
            },
            {
                "content": "When your exam reports are ready to view, they will appear in your account. You will get an email notification when they are available to view, with a link to the relevant documents in the new service. You will have to be logged into your account to access the documents.\u00a0",
                "tag": "p"
            },
            {
                "content": "When you\u2019re ready to respond to the exam report, you will upload your response by uploading your response documents via your account.\u00a0",
                "tag": "p"
            },
            {
                "content": "Access controls and sharing\u00a0",
                "tag": "h3"
            },
            {
                "content": "You will be able to set access controls on SPCs using the \u2018groups\u2019 functionality in the service. For example, if access to SPC applications should be limited to specific people in your firm, you can create an SPC group, which only the relevant people have access to.\u00a0",
                "tag": "p"
            },
            {
                "content": "However, you won\u2019t be able to save and share draft applications when applying for SPCs at this time.\u00a0",
                "tag": "p"
            }
        ],
        "link": "https://ipo.blog.gov.uk/2025/10/28/whats-changing-supplementary-protection-certificates/",
        "blog": "Intellectual Property Office blog",
        "blog_link": "https://ipo.blog.gov.uk",
        "description": "Our One IPO Patent Service, is set to launch in Spring 2026, we are providing weekly guidance to help you prepare for these changes. This week we're looking at SPCs."
    },
    {
        "title": "Cartels: being first to apply for leniency matters more than ever",
        "authors": [
            "Lucilia Falsarella Pereira"
        ],
        "posted_on": "2025-10-28T11:00:48",
        "categories": [
            "Competition Act 1998 and cartels"
        ],
        "content": [
            {
                "content": "The Competition and Markets Authority's (CMA) leniency regime is a powerful tool in the fight against cartels.",
                "tag": "p"
            },
            {
                "content": "Since the publication of our previous leniency guidance 12 years ago, we have received nearly 250 leniency applications. Cases with leniency applicants have resulted in more than \u00a3355 million in financial penalties and the disqualification of 24 company directors.",
                "tag": "p"
            },
            {
                "content": "Following a public consultation, we have updated our leniency guidance to:",
                "tag": "p"
            },
            {
                "content": "Cartel enforcement: a CMA priority",
                "tag": "h2"
            },
            {
                "content": "Cartels are a particularly damaging form of anti-competitive activity, where rivals agree not to compete so they can gain an unfair advantage. This can lead to higher prices and deprive people of genuine choice, as well as reduce incentives for business efficiency, investment and innovation.",
                "tag": "p"
            },
            {
                "content": "The CMA is committed to tackling harmful cartels, so that fair-dealing businesses can innovate and thrive \u2013 boosting the economy \u2013 and individuals can be confident that they are getting great choices and fair deals.",
                "tag": "p"
            },
            {
                "content": "An effective leniency regime is a crucial part of our strategy to detect and enforce against cartels and it helps ensure that we reach robust outcomes in an efficient way. The leniency regime also helps deter cartels, by making it riskier to be involved in one.",
                "tag": "p"
            },
            {
                "content": "We proactively detect cartels",
                "tag": "h2"
            },
            {
                "content": "While leniency will always play an important role in the fight against cartels, it is far from being the only way the CMA detects them. Indeed, over the years we have kept a fairly even balance between own-initiative cases and those that start with a leniency application.",
                "tag": "p"
            },
            {
                "content": "Our detection work includes, for example:",
                "tag": "p"
            },
            {
                "content": "That means we\u2019re finding and stopping harmful cartels regardless of whether a cartelist decides to blow the whistle and apply for leniency \u2013 which is why it is important to come forward at the earliest opportunity.",
                "tag": "p"
            },
            {
                "content": "Being first to apply for leniency matters more than ever",
                "tag": "h2"
            },
            {
                "content": "The changes we have introduced mean that being a Type A applicant (that is, the first to apply for leniency before the CMA has started to investigate) is the only way to get guaranteed immunity from:",
                "tag": "p"
            },
            {
                "content": "Uncovering cartel conduct and adopting a \u2018wait and see\u2019 approach by applying for leniency only after a CMA investigation has begun now carries greater risk for businesses.",
                "tag": "p"
            },
            {
                "content": "We have removed the availability of upfront immunity for Type B applicants (that is, those who are the first applicant but who have only come forward after we have started to investigate) and clarified that Type B discounts are unlikely to be above 75% (reflecting our practice to date).",
                "tag": "p"
            },
            {
                "content": "We have also removed automatic director disqualification protection for Type B and C applications (Type C applicants are those who apply after the first applicant). Such protection is now discretionary and will ensure that directors are only immunised from disqualification when this is in the public interest, thereby protecting the public by removing unfit directors.",
                "tag": "p"
            },
            {
                "content": "Making our guidance clearer and processes better",
                "tag": "h2"
            },
            {
                "content": "We also wanted to ensure that the leniency guidance is as clear, accessible and user-friendly as possible. We have done this by:",
                "tag": "p"
            },
            {
                "content": "Another important update was to the definition of \u2018cartel activity\u2019, so that it reflects the latest case law and CMA guidance and practice, while being flexible enough to cover cartel conduct that may be considered to fall within the policy in the future. We have also provided more examples of the types of conduct for which leniency is available. This includes conduct in labour markets, algorithmic collusion and agreements to limit innovation \u2013 for example, in order to meet or exceed a sustainability goal.",
                "tag": "p"
            },
            {
                "content": "We also no longer require applicants to confess at the start \u2013 something that the business community very clearly told us could have discouraged applications. This is now only needed when signing the leniency agreement, usually just before we issue the statement of objections.",
                "tag": "p"
            },
            {
                "content": "If you are thinking of applying and would like more clarity on specific points, we are happy to provide confidential guidance.",
                "tag": "p"
            },
            {
                "content": "Act now",
                "tag": "h2"
            },
            {
                "content": "If you suspect you, your business or a client you advise is involved in cartel activity:",
                "tag": "p"
            }
        ],
        "link": "https://competitionandmarkets.blog.gov.uk/2025/10/28/cartels-being-first-to-apply-for-leniency-matters-more-than-ever/",
        "blog": "Competition and Markets Authority",
        "blog_link": "https://competitionandmarkets.blog.gov.uk",
        "description": "Our updated leniency guidance creates stronger incentives to apply for leniency before the CMA opens an investigation."
    },
    {
        "title": "A Century of Occupational Therapy: Why the Next 100 Years Matter More Than Ever\u00a0",
        "authors": [
            "Sarah McClinton"
        ],
        "posted_on": "2025-10-27T15:53:48",
        "categories": [
            "Care and support",
            "Communities",
            "Knowledge and skills",
            "Recognition",
            "Society",
            "Viewpoint"
        ],
        "content": [
            {
                "content": "Introduction",
                "tag": "h2"
            },
            {
                "content": "To coincide with World Occupational Therapy Day, Carolyne Hague outlines the vital contribution that occupational therapy makes to people\u2019s lives and sets out her call to action, emphasising the importance of a collective voice that includes occupational therapists alongside communities, social workers, nurses, policymakers and others to shape a national health and care system that reflects the values of inclusion, innovation and independence.\u00a0As co-chair of the Principal OT network, Carolyne has made an outstanding contribution to raising the profile of OTs in adult services and we will miss her as she moves into her new role in the NHS.",
                "tag": "p"
            },
            {
                "content": "From Radical Beginnings to System Shapers\u00a0",
                "tag": "h2"
            },
            {
                "content": "Our story began in the 1920s, with pioneers like Dr Elizabeth Casson who believed \u2014 radically at the time \u2014 that meaningful occupation could heal and empower. That belief became the foundation of a profession that\u2019s grown alongside the welfare state, through landmark legislation like the 1948 National Assistance Act, the 1970 Chronically Sick and Disabled Persons Act, and the Care Act 2014.\u00a0\u00a0",
                "tag": "p"
            },
            {
                "content": "Occupational therapists are solution-focused. We see the person first, their strengths, goals, and potential and work creatively to remove barriers and enable independence. In adult social care, we\u2019re uniquely placed to turn policy into real-life outcomes, helping people live safely, independently and with purpose. Whether it\u2019s through home adaptations, equipment and technology provision, moving and handling skills, reablement, or creative thinking to promote the independence of people with long term conditions, we bring wellbeing to life.\u00a0\u00a0",
                "tag": "p"
            },
            {
                "content": "Policy, Economic Contribution and Impact\u00a0",
                "tag": "h2"
            },
            {
                "content": "Occupational therapists are not only improving lives, they are also shaping systems and contributing to economic growth. By enabling people to live independently, return to work and avoid crisis care, occupational therapy reduces long-term costs and supports financial sustainability. From preventing hospital admissions, future proofing housing stock, improving practice quality, reducing reliance on statutory services and improving system efficiency through early intervention and prevention, the profession plays a vital role in system design and delivery.\u00a0",
                "tag": "p"
            },
            {
                "content": "Building a National Voice\u00a0",
                "tag": "h2"
            },
            {
                "content": "Five years ago, a group of us came together with a simple but bold ambition: to create a national voice for occupational therapists in adult social care leadership. We wanted to be seen not just as practitioners, but as strategic leaders shaping the future of care.\u00a0",
                "tag": "p"
            },
            {
                "content": "Through the National Principal Occupational Therapy Network, we\u2019ve built a thriving community of leaders. We\u2019ve strengthened relationships with the Department of Health and Social Care (DHSC), ADASS, NHS England, the Principal Social Worker and Approved Mental Health Professional networks, Royal College of Occupational Therapists and the Local Government Association. We\u2019ve highlighted the evidence and impact of occupational therapy in prevention, reablement, and community wellbeing. We\u2019ve created space for mentoring, peer learning, and innovation. And we\u2019ve made sure our voice is heard in national policy \u2014 influencing integration and workforce reforms, the NHS Long Term Plan, and the future of social care.\u00a0",
                "tag": "p"
            },
            {
                "content": "From reflection to action\u00a0",
                "tag": "h2"
            },
            {
                "content": "As we celebrate 100 years of occupational therapy, we must honour the legacy of those who came before us, not by looking back, but by stepping forward.\u00a0",
                "tag": "p"
            },
            {
                "content": "Here\u2019s my call to action:\u00a0",
                "tag": "p"
            },
            {
                "content": "Influence: Bring practical, person-centred solutions into the heart of system design.\u00a0",
                "tag": "p"
            },
            {
                "content": "Innovate: Use our occupational therapy creativity to reshape care pathways, housing, and community models.\u00a0",
                "tag": "p"
            },
            {
                "content": "Collaborate and connect: Use our collaborative leadership, system navigation skills and experience working across health, housing, and social care to build stronger relationships, communities and prevention-focused services.\u00a0",
                "tag": "p"
            },
            {
                "content": "Inspire: Mentor and empower others \u2014 so the next generation of occupational therapists and occupational therapy leaders is even stronger.\u00a0",
                "tag": "p"
            },
            {
                "content": "Looking Ahead\u00a0",
                "tag": "h2"
            },
            {
                "content": "We\u2019re standing at a powerful moment in history. A century behind us. A century ahead. And a national network of leaders ready to shape what comes next.\u00a0",
                "tag": "p"
            },
            {
                "content": "Occupational therapy has always been about enabling people to live \u2014 not just exist. Our role in adult social care has never been more vital, and our collective influence has never been more needed.\u00a0\u00a0",
                "tag": "p"
            },
            {
                "content": "As we look ahead, we must work together with our communities, occupational therapists, social workers, nurses, policymakers, DHSC and other stakeholders to shape a national health and care system that truly reflects the values of inclusion, innovation and independence. Our collective voice is essential in designing policies and partnerships that enable people to live well. Let\u2019s do things differently this time and ensure occupational therapy is embedded in every conversation about the future of care, and that our insights drive meaningful change across the system.\u00a0",
                "tag": "p"
            },
            {
                "content": "Because the future of adult social care needs our voice \u2014 grounded in occupation, driven by values, and focused on what matters most: people\u2019s lives.\u00a0\u00a0",
                "tag": "p"
            },
            {
                "content": "This Local Government Association report, developed in partnership with national and regional occupational therapy leaders, explores the unique role of occupational therapists in councils. It highlights their impact across housing, health, care, and employment, and sets out what the Government can do to unlock their full potential and support delivery of their missions - Occupational therapists in councils: Unlocking capacity and driving change | Local Government Association\u00a0",
                "tag": "p"
            }
        ],
        "link": "https://socialworkwithadults.blog.gov.uk/2025/10/27/a-century-of-occupational-therapy-why-the-next-100-years-matter-more-than-ever/",
        "blog": "Social work with adults",
        "blog_link": "https://socialworkwithadults.blog.gov.uk",
        "description": "Introduction To coincide with World Occupational Therapy Day, Carolyne Hague outlines the vital contribution that occupational therapy makes to people\u2019s lives and sets out her call to action, emphasising the importance of a collective voice that includes occupational therapists alongside \u2026"
    },
    {
        "title": "Coverage of Awaab\u2019s Law announcement",
        "authors": [
            "mhclgpress"
        ],
        "posted_on": "2025-10-27T14:42:49",
        "categories": [
            "Uncategorized"
        ],
        "content": [
            {
                "content": "There has been widespread national, regional and broadcast coverage today on the department\u2019s announcement\u00a0on new laws now in force protecting social housing tenants from emergency hazards and damp and mould.",
                "tag": "p"
            },
            {
                "content": "Awaab\u2019s Law is a legacy to two-year-old Awaab Ishak who tragically died from prolonged exposure to mould and the reforms will improve the lives for tenants and families living in all four million of England\u2019s social rented homes.",
                "tag": "p"
            },
            {
                "content": "The changes mean landlords must fix emergency health and safety hazards within 24 hours of reporting, while they must also investigate significant damp and mould within 10 working days of being notified and then make properties safe in five working days.\u00a0",
                "tag": "p"
            },
            {
                "content": "National coverage can be seen in The Guardian, The Independent\u00a0and The I who report the government has committed to extending Awaab\u2019s law to the private rented sector through the Renters\u2019 Rights Bill. The Mirror\u00a0and Sky News\u00a0also focus on Awaab\u2019s story with comments from his father in the pieces, while Sky News\u00a0have also run an explainer video sharing the story.",
                "tag": "p"
            },
            {
                "content": "An op-ed from the Secretary of State is carried in Manchester Evening News on the \u2018tragedy\u2019 and \u2018moment of shame for Britain\u2019 when Awaab Ishak died in 2020. The piece states, \u2018this can never happen again\u2019 and praises Awaab\u2019s parents for \u2018their incredible fight for justice\u2019.",
                "tag": "p"
            },
            {
                "content": "Elsewhere, in broadcast coverage BBC News\u00a0has run an in-depth piece on the introduction of Awaab\u2019s Law and the history behind its name and carries comment from the Secretary of State highlighting the law will give tenants a \u2018stronger voice and force landlords to act urgently when lives are at risk\u2019. ITV News hasalso reported on the new rules coming into effect, focusing on the \u00a31 million fund aimed at creating new ways of helping tenants engage with their landlords and have more influence over decisions affecting them.",
                "tag": "p"
            },
            {
                "content": "The Big Issue\u00a0carry a piece by Joe Carpenter, an author and previous social housing maintenance worker, who wrote of his experience working on the frontline and seeing the challenges faced by the sector first hand.",
                "tag": "p"
            },
            {
                "content": "The Secretary of State took part in the morning broadcast round and was interviewed by Times Radio, Sky News, BBC Breakfast, LBC, Radio 4 Today programme, Good Morning Britain, Bauer and GB News, with much of the focus on Awaab\u2019s Law.",
                "tag": "p"
            },
            {
                "content": "Housing Secretary Steve Reed said:\u202f\u202f\u00a0",
                "tag": "p"
            },
            {
                "content": "\u201cEveryone deserves a safe and decent home to live in and Awaab Ishak is a powerful reminder of how this can sadly be a matter of life or death.\u00a0",
                "tag": "p"
            },
            {
                "content": "\u201cAwaab\u2019s family has fought hard for change and their work to protect millions of tenants\u2019 lives will live on as a legacy to their son.\u202f\u00a0",
                "tag": "p"
            },
            {
                "content": "\u201cOur changes will give tenants a stronger voice and force landlords to act urgently when lives are at risk, ensuring such tragedies are never repeated.\u201d",
                "tag": "p"
            }
        ],
        "link": "https://mhclgmedia.blog.gov.uk/2025/10/27/coverage-of-awaabs-law-announcement/",
        "blog": "MHCLG in the Media",
        "blog_link": "https://mhclgmedia.blog.gov.uk",
        "description": "There has been widespread national, regional and broadcast coverage today on the department\u2019s announcement\u00a0on new laws now in force protecting social housing tenants from emergency hazards and damp and mould. Awaab\u2019s Law is a legacy to two-year-old Awaab Ishak who \u2026"
    },
    {
        "title": "A milestone in the fight against antimicrobial resistance (AMR)",
        "authors": [
            "Ramon Maluping"
        ],
        "posted_on": "2025-10-27T09:16:08",
        "categories": [
            "Antimicrobial Resistance",
            "International"
        ],
        "content": [
            {
                "content": "What is antimicrobial resistance and why does it matter?",
                "tag": "h2"
            },
            {
                "content": "Antimicrobial resistance (AMR) is not just a scientific buzzword; it is a global crisis. When bacteria, viruses, fungi, and parasites outsmart antimicrobials (for example antibiotics), infections become harder or impossible to treat, diseases spread faster, and lives hang in the balance.",
                "tag": "p"
            },
            {
                "content": "Its impact is far-reaching: AMR threatens human health, animal welfare, food security and the environment. By 2050, the World Bank predicts it could reduce the GDP of low-income countries by more than five percent and push millions into poverty.",
                "tag": "p"
            },
            {
                "content": "One of the most important tools for monitoring AMR is antimicrobial susceptibility testing (AST). This involves isolating bacteria and exposing them to different antibiotics to determine which are effective. Reliable AST results are essential because they guide treatment, track resistance trends and help assess infection prevention measures, such as improved farm biosecurity. Standardised AST methods also enable laboratories worldwide to compare data, providing a clearer picture of how resistance spreads.",
                "tag": "p"
            },
            {
                "content": "A UK\u2013Philippines collaboration",
                "tag": "h2"
            },
            {
                "content": "Since 2022, the UK FAO Reference Centre for AMR has worked closely with the Philippines. Supporting the UK\u2019s 2024 to 2029 National Action Plan (NAP) on AMR, which emphasises global partnerships, the Centre has been actively engaged in the implementation of the Philippines\u2019 own 2024\u20132028 NAP. This includes strengthening laboratory capacity, improving surveillance systems and generating reliable AST data.",
                "tag": "p"
            },
            {
                "content": "The Philippines launched its first-ever national training workshop on antimicrobial susceptibility testing (AST) in July 2025 in Quezon City, Metro Manila. Lead by the Department of Agriculture \u2013 National Meat Inspection Service (DA-NMIS) and co-organised with the UK\u2019s FAO Reference Centre for AMR and was supported by Scientific Biotech Specialties Inc. (SBSI), Thermo Fisher Scientific and the Department of Agriculture \u2013 Bureau of Animal Industry (DA-BAI). The workshop drew on the scientific knowledge of the Animal and Plant Health Agency (APHA), Cefas, and the Veterinary Medicines Directorate (VMD) to equip participants with the tools to tackle AMR head-on and brought together cutting-edge expertise and international collaboration with partners",
                "tag": "p"
            },
            {
                "content": "The workshop became a hub of expertise; drawing veterinarians, scientists, and lab professionals from every corner of the Philippines. A total of 32 participants representing 28 institutions (including national and regional government bodies, academia, Food and Agriculture Organization\u00a0(FAO), and private sector leaders) came together in a powerful show of unity. With backgrounds spanning terrestrial and aquatic animal health, environmental science, and public health, the cohort embodied a truly multidisciplinary force. The event also underscored a critical message: when government and industry join forces, the potential to elevate laboratory capacity and fight AMR multiplies.",
                "tag": "p"
            },
            {
                "content": "Across three days of lectures and practical sessions, participants strengthened technical skills and built lasting connections across animal, aquatic and food sectors. The workshop marked a turning point in harmonising laboratory methods nationwide and generating the high-quality data needed to guide treatment decisions, protect food systems and safeguard public health. The workshop demonstrated the progress possible through shared expertise and commitment.",
                "tag": "p"
            },
            {
                "content": "Recently, the centre also co-delivered another highly successful AST training workshop on bacterial pathogens affecting aquatic animals, serving AMR National Reference Laboratories from 11 countries across the Asia\u2013Pacific region.",
                "tag": "p"
            },
            {
                "content": "Learning through theory and practice",
                "tag": "h2"
            },
            {
                "content": "APHA scientists Dr. Ramon P. Maluping and Dr. Thomas Chisnall with Cefas counterparts Dr. Athina Papadopoulou and Dr. Andy Powell led the training and served as resource speakers, supported by colleagues from NMIS, BAI, SBSI and Thermo Fisher. The programme combined theory with hands-on practice, equipping participants with both the knowledge and confidence to conduct AST in their own laboratories.",
                "tag": "p"
            },
            {
                "content": "In lectures, trainers explained the science behind AST, introduced the international standards: Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST), and highlighted the role of control strains in ensuring accurate results. Participants explored both manual and automated testing methods and learned how to interpret results using clinical breakpoints and epidemiological cut-off values. This theoretical foundation showed how AST data strengthens national surveillance and supports the responsible use of antibiotics.",
                "tag": "p"
            },
            {
                "content": "The hands-on sessions made the topics much easier to understand. Each participant carried out AST using a commercially available Sensititre system. They prepared the samples, set up the testing plates, and measured the minimum amount of antibiotic needed to stop bacterial growth (MIC).",
                "tag": "p"
            },
            {
                "content": "The trainers guided everyone through each step, stressing the importance of doing the test correctly, recording results carefully, and following quality checks using control bacteria.",
                "tag": "p"
            },
            {
                "content": "Participants also did simple biochemical tests to confirm the type of bacteria and discussed how sharing AST results between laboratories helps strengthen the national surveillance system in the Philippines. The combination of classroom teaching and practical lab work helped reinforce what they learned through real-world application.",
                "tag": "p"
            },
            {
                "content": "Voices from the workshop",
                "tag": "h2"
            },
            {
                "content": "The response from participants was overwhelmingly positive. One commented:",
                "tag": "p"
            },
            {
                "content": "Another said:",
                "tag": "p"
            },
            {
                "content": "Others praised the diversity of expertise in the room:",
                "tag": "p"
            },
            {
                "content": "Key takeaways included new technical skills such as interpreting MICs, applying CLSI and EUCAST standards correctly, and understanding why every AST must be backed by quality control data. The workshop also deepened awareness of both passive and active AMR surveillance and reinforced the importance of using antibiotics responsibly.",
                "tag": "p"
            },
            {
                "content": "Building a stronger future together",
                "tag": "h2"
            },
            {
                "content": "The Philippines workshop not only strengthened individual laboratory skills but also encouraged collaboration across animal health, aquaculture, food safety and academia. It demonstrated the value of a One Health approach, which recognises that human, animal and environmental health are interconnected.",
                "tag": "p"
            },
            {
                "content": "By helping deliver the Philippines\u2019 first national AST training workshop, the UK FAO Reference Centre for AMR has supported a vital step forward in the country\u2019s AMR response. With harmonised methods and stronger laboratory capacity, the Philippines is now better positioned to generate reliable data, guide treatment decisions and support more sustainable food systems.",
                "tag": "p"
            },
            {
                "content": "Through continued partnership, the Philippines and the UK, share a commitment to building the knowledge and capacity needed to tackle AMR \u2013 protecting health, livelihoods and the environment for generations to come.",
                "tag": "p"
            }
        ],
        "link": "https://aphascience.blog.gov.uk/2025/10/27/a-milestone-in-the-fight-against-antimicrobial-resistance/",
        "blog": "APHA Science Blog",
        "blog_link": "https://aphascience.blog.gov.uk",
        "description": "APHA's Ramon Maluping talks about how a UK\u2013Philippines workshop empowered labs with vital skills to combat antimicrobial resistance and protect health, food systems, and the environment."
    }
]